F

ile this under “three strikes and you’re out!”

Twice last fall, the House Committee on Oversight and Government Reform asked Mylan Pharmaceuticals to submit documents about EpiPen pricing, but to date, the company has provided precious few. So last Friday, the committee warned Mylan attorneys that, if the company does not comply, a subpoena may be issued for Mylan execs to testify and produce the documents.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • gag me why are they allowed to exclude the government settlement from their bonus calculation? This is nothing more than a catch up of a business expense or adjustment downward to revenue that should have taken place years ago.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.